Comparison of ever present clinical characteristics between SSc patient groups stratified by antibody status. Values are n (%) unless otherwise specified.
| Characteristics | Total Cohort | RNAP | ACA | ATA | Other Ab | No Ab | pa | pb |
|---|---|---|---|---|---|---|---|---|
| No. patients | 279 | 33 (12) | 134 (48) | 46 (16) | 55 (20) | 11 (4) | ||
| Age at disease onset, yrs, mean (SD) | 49 (15.3) | 46 (13.6) | 52 (14.1) | 46 (16.1) | 45 (17.4) | 52 (15.0) | 0.909 | 0.050 |
| Disease duration at baselinec, yrs, mean (SD) | 5.5 (6.8) | 3.3 (3.4) | 5.2 (6.7) | 6.2 (7.4) | 6.3 (7.3) | 7.6 (8.8) | 0.027 | 0.120 |
| Disease duration at followupc, yrs, mean (SD) | 9.9 (7.5) | 8.2 (5.1) | 9.5 (7.3) | 10.4 (8.8) | 11.1 (8.4) | 11.5 (10.4) | 0.155 | 0.335 |
| Disease duration < 3 yrs at baseline | 147 (53) | 20 (65) | 70 (60) | 24 (56) | 28 (51) | 6 (55) | 0.470 | 0.617 |
| Males | 59 (21) | 7 (21) | 24 (18) | 13 (28) | 12 (22) | 3 (27) | 0.477 | 0.662 |
| Dead | 66 (24) | 6 (18) | 24 (18) | 14 (30) | 13 (24) | 9 (82) | 0.217 | 0.971 |
| Diffuse cutaneous SSc | 76 (21) | 26 (79) | 8 (16) | 24 (52) | 13 (24) | 5 (46) | 0.016 | < 0.001 |
| Modified Rodnan skin score, mean (SD)d | 9.0 (8.8) | 18.0 (11.9) | 5.9 (6.8) | 10.8 (7.7) | 8.1 (6.1) | 16.8 (12.3) | 0.002 | < 0.001 |
| Renal crisis | 10 (4) | 9 (27) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | < 0.001 | < 0.001 |
| Digital ulcers | 123 (44) | 15 (46) | 58 (43) | 22 (48) | 25 (46) | 3 (27) | 0.096 | 0.650 |
| GAVE | 18 (7) | 5 (16) | 8 (6) | 1 (2) | 4 (7) | 1 (9) | 0.036 | 0.068 |
| Esophagus dysmotility | 202 (72) | 27 (82) | 96 (72) | 30 (65) | 42 (76) | 7 (64) | 0.069 | 0.624 |
| Dysphagia | 137 (49) | 17 (52) | 66 (49) | 16 (35) | 32 (58) | 6 (55) | 0.132 | 0.799 |
| GERD | 138 (50) | 19 (58) | 61 (46) | 25 (54) | 28 (51) | 5 (46) | 0.785 | 0.413 |
| Malignancies | 49 (18) | 7 (23) | 24 (19) | 7 (16) | 9 (16) | 2 (18) | 0.495 | 0.688 |
↵a p values between RNAP and ATA.
↵b p values between RNAP and ACA.
↵c Time from onset of first non-Raynaud symptom to baseline or followup consultation.
↵d Estimated at baseline. SSc: systemic sclerosis; RNAP: RNA polymerase III; ACA: anticentromere antibody; ATA: antitopoisomerase I; Ab: antibody; GAVE: gastric antral vascular ectasia; GERD: gastroesophageal reflux disease.